Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds

A method for treating a solid tumor cancer in a human individual using a therapeutic compound of any of formule (I)-(Io) or (IIa)-(IIe), the method comprising:

• determining the level of expression of FAM210B of the cancer;
• determining a FAM210B expression fold change as compared to the level of expression of FAM210B in a reference cell;
• and
• if the FAM210B expression fold change is significant, and if FAM210B expression in the cancer is lower than FAM210B expression in the reference cell, administering an effective amount of the therapeutic compound to the human individual.

A method for determining whether a solid tumor cancer is responsive to a therapeutic compound of any of formule (I)-(Io) or (IIa)-(IIe), the method comprising:

• determining the level of expression of FAM210B of the cancer;
• determining a FAM210B expression fold change as compared to the level of expression of FAM210B in a reference cell;
• and
• if the FAM210B expression fold change is significant, and if FAM210B expression in the cancer is lower than FAM210B expression in the reference cell, identifying the cancer as likely to be responsive to the therapeutic compound.

A method for treating a hematopoietic cancer in a human individual, comprising:

• determining the level of expression of a plurality of genes of the cancer;
• determining a gene expression fold change as compared to the level of expression of the plurality of genes in a reference cell;
• and
• if the gene expression fold change is significant with respect to a first number of the plurality of genes, administering an effective amount of a therapeutic compound of any of formule (I)-(Io) or (IIa)-(IIe) to the human individual, the first number being five or more,
• wherein the cancer is a hematopoietic cancer that exhibits a significant gene expression fold change as compared to a reference cell with respect to a first number of a plurality of genes selected from CASP10, TMED1, PPP1CC, TMEM59, BRD7, CYB561, FAM210B, NDRG1, CTSB, MMAB, SETDB2, VPS37B, ELL3, and KIF13B, wherein the first number is at least five.

A method for determining whether a hematopoietic cancer is responsive to a therapeutic compound of any of formule (I)-(Io) or (IIa)-(IIe), the method comprising:

• determining the level of expression of a plurality of genes of the cancer;
• determining a gene expression fold change as compared to the level of expression of the one or more genes in a reference cell;
• and
• if the gene expression fold change is significant with respect to a first number of the plurality of genes, identifying the cancer as likely to be responsive to the therapeutic compound, wherein the first number is five or more,
• wherein the cancer is a hematopoietic cancer that exhibits a significant gene expression fold change as compared to a reference cell with respect to a first number of a plurality of genes selected from CASP10, TMED1, PPP1CC, TMEM59, BRD7, CYB561, FAM210B, NDRG1, CTSB, MMAB, SETDB2, VPS37B, ELL3, and KIF13B, wherein the first number is at least five.

A method for treating a solid tumor cancer in a human individual, comprising:

• determining the level of expression of a plurality of genes of the cancer;
• determining a gene expression fold change as compared to the level of expression of the plurality of genes in a reference cell;
• and
• if the gene expression fold change is significant with respect to a first number of the plurality of genes, administering an effective amount of a therapeutic compound of any of formule (I)-(Io) or (IIa)-(IIe) to the human individual, the first number being five or more,
• wherein the cancer is a solid tumor cancer that exhibits a significant gene expression fold change as compared to a reference cell with respect to a first number of a plurality of genes selected from LAMC3, FAM210B, SENP8, ITGB3BP, NUDT2, HNRNPCL1, C20orf43, FRMD8, and STX16, wherein the first number is at least five.

A method for determining whether a solid tumor cancer is responsive to a therapeutic compound of any of formule (I)-(Io) or (IIa)-(IIe), the method comprising:

• determining the level of expression of a plurality of genes of the cancer;
• determining a gene expression fold change as compared to the level of expression of the one or more genes in a reference cell;
• and
• if the gene expression fold change is significant with respect to a first number of the plurality of genes, identifying the cancer as likely to be responsive to the therapeutic compound, wherein the first number is five or more,
• wherein the cancer is a solid tumor cancer that exhibits a significant gene expression fold change as compared to a reference cell with respect to a first number of a plurality of genes selected from LAMC3, FAM210B, SENP8, ITGB3BP, NUDT2, HNRNPCL1, C20orf43, FRMD8, and STX16, wherein the first number is at least five.